Chetasi Talati, MD, Moffit Cancer Center, reviews the use of venetoclax, a BCL-2 inhibitor, for the treatment of acute myeloid leukemia (AML). Venetoclax has been approved for the treatment of chronic lymphocytic leukemia and other hematologic malignancies and is now in phase 3 clinical trials for the treatment of AML as researchers have found high expression of BCL-2 in leukemic cells. Dr. Talati says combination therapies using venetoclax with other agents could be a "game-changer" for the field.

Click here to learn more.